Drug news
Nexavar (Bayer/Onyx) fails to improve overall survival in MISSION study for NSCLC
Bayer HealthCare and Onyx Pharmaceuticals, announced that the Phase III MISSION trial evaluating Nexavar (sorafenib) tablets in patients with advanced relapsed or refractory non-squamous Non-Small Cell Lung Cancer whose disease progressed after two or three previous treatments, did not meet its primary endpoint of improving overall survival. An improvement in the secondary endpoint of progression-free survival was observed.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.